Alain Cantagrel

IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial

Paul Emery, Edward Keystone, Hans‐Peter Tony et al. · Annals of the Rheumatic Diseases · 2008 · 1.1K citations · Full text

Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial

Peter Nash, Bruce Kirkham, Masato Okada et al. · The Lancet · 2017 · 390 citations · Full text

Rheumatoid Disorder, Rheumatology, Spirit-p2 Phase 3 +12

Risk factors for severe infections in patients with rheumatoid arthritis treated with rituximab in the autoimmunity and rituximab registry

Jacques‐Eric Gottenberg, Philippe Ravaud, Thomas Bardin et al. · Arthritis & Rheumatism · 2010 · 296 citations

Prognostic factors for radiographic damage in early rheumatoid arthritis: A multiparameter prospective study

Bernard Combe, Maxime Dougados, Philippe Goupille et al. · Arthritis & Rheumatism · 2001 · 283 citations

Interleukin-1?, interleukin-1 receptor antagonist, interleukin-4, and interleukin-10 gene polymorphisms: Relationship to occurrence and severity of rheumatoid arthritis

Alain Cantagrel, F Navaux, Patrick Loubet-Lescouli� et al. · Arthritis & Rheumatism · 1999 · 264 citations